Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.130279 USD
−71.89 M USD
59.73 M USD
193.39 M
About Keymed Biosciences, Inc.
Sector
Industry
CEO
Bo Chen
Website
Headquarters
Chengdu
Founded
2018
ISIN
KYG5252B1023
FIGI
BBG01C35N109
Keymed Biosciences, Inc. is an investment holding company, which engages in the discovery and development of biological therapies in the autoimmune and oncology therapeutic areas. It operates through Hong Kong and China geographical segment. The company was founded on April 23, 2018 and is headquartered in Chengdu, China.
Related stocks
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
513120
GF CSI Hong Kong Brand Name Drug Exchange Traded Fund UnitsWeight
1.06%
Market value
20.17 M
USD
159892
ChinaAMC Hang Seng Hong Kong-Listed Biotech Index ETF Units AWeight
0.78%
Market value
4.95 M
USD
159567
Yinhua China Sec Hong Kong Stock Connect Innovative Drug EtfWeight
1.08%
Market value
4.44 M
USD
513200
E Fund CSI HK Connect Health Care Composite Exchange Traded Fund UnitsWeight
0.84%
Market value
2.65 M
USD
UIC1
UBS (Lux) Fund Solutions SICAV - UBS Solactive China Technology UCITS ETF hEUR acc- CapitalisationWeight
0.23%
Market value
1.85 M
USD
513780
INVESCO Great Wall CSI Hong Kong Connect Innovative Drug Exchange Traded Fund UnitsWeight
1.13%
Market value
1.73 M
USD
Explore more ETFs
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange KEYMED BIOSCIENCES INC. stocks are traded under the ticker KEYBF.
We've gathered analysts' opinions on KEYMED BIOSCIENCES INC. future price: according to them, KEYBF price has a max estimate of 12.11 USD and a min estimate of 11.72 USD. Watch KEYBF chart and read a more detailed KEYMED BIOSCIENCES INC. stock forecast: see what analysts think of KEYMED BIOSCIENCES INC. and suggest that you do with its stocks.
Yes, you can track KEYMED BIOSCIENCES INC. financials in yearly and quarterly reports right on TradingView.
KEYMED BIOSCIENCES INC. is going to release the next earnings report on Mar 31, 2026. Keep track of upcoming events with our Earnings Calendar.
KEYBF net income for the last half-year is −10.79 M USD, while the previous report showed −24.92 M USD of net income which accounts for 56.72% change. Track more KEYMED BIOSCIENCES INC. financial stats to get the full picture.
No, KEYBF doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 9, 2025, the company has 1.26 K employees. See our rating of the largest employees — is KEYMED BIOSCIENCES INC. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. KEYMED BIOSCIENCES INC. EBITDA is −34.49 M USD, and current EBITDA margin is −122.60%. See more stats in KEYMED BIOSCIENCES INC. financial statements.
Like other stocks, KEYBF shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade KEYMED BIOSCIENCES INC. stock right from TradingView charts — choose your broker and connect to your account.